With the era of molecularly targeted therapy clearly established, prostate cancer is currently emerging as a forefront of discovery and implementation of personalized medicine strategies designed to individually select the best available treatment for each patient. This is the first book of its kind to focus on the molecular aspects of prostate cancer and how genetics, genomics and proteomics interact in the predisposition, development, progression and response to therapy of the disease. It emphasizes the genes, proteins and biologic pathways that are being evaluated today and will be tested in the future to derive the molecular signature of each newly diagnosed prostate cancer. This single volume offers readers relevant, up-to-date information on how these molecular-based tests are being used to discover the predisposition for developing the disease, how to detect it at the earliest stage possible, how to classify it based on its genetic fingerprint, and how to predict its therapy-specific outcome.